Rally Foundation’s Advocacy
Your voice matters and here’s proof:
$317.5 Million
Rally Foundation leads the charge for funding from the Department of Defense (DOD) Congressionally Directed Medical Research Program (CDMRP). In eight years, our collective voices have secured $317.5 million for cancers that affect children, adolescents and young adults resulting in 269 new federally-funded research projects.
Helpful Submission Tips and Insights
Rally hosted a webinar with Julie Huiberts, PRCRP Program Manager. Ms. Huiberts provided expert insights and best practices for completing and submitting your DOD grant application. Since the webinar, programmatic changes have occurred. A new webinar recording will be forthcoming and the slides below have been updated to reflect all programmatic changes.
Rally’s DOD Efforts Since 2017
DOD Peer Reviewed Cancer Research Program (PRCRP)
| YEAR | PRCRP BUDGET | # OF ELIGIBLE CATEGORIES (CANCERS) | PEDIATRIC & AYA CANCERS | PEDIATRIC BRAIN TUMORS | NEUROBLASTOMA | TOTAL OF PRCRP BUDGET |
|---|---|---|---|---|---|---|
| 2024* | $130M | 18 | $63.8M 28 Awards |
$2.6M 3 Awards |
$9.4M 11 Awards |
$75.8M |
| 2023 | $130M | 20 | $57M 42 Awards |
$10.2M 8 Awards |
$3.9M 3 Awards |
$67.4M |
| 2022 | $130M | 20 | $50.9M 44 Awards |
$4.8M 5 Awards |
$0.6M 1 Award |
$41.25M |
| 2021 | $130M | 20 | $46.1M 36 Awards |
$3.4M 3 Awards |
$6.5M 5 Awards |
$56M |
| 2020 | $110M | 14 | $10.8M 12 Awards |
$6.05M 7 Awards |
$4.8M 3 Awards |
$21.65M |
| 2019 | $90M | 15 | $7.5M 10 Awards |
$3.4M 5 Awards |
$4.9M 7 Awards |
$15.8M |
| 2018 | $80M | 17 | $6.5M 11 Awards |
$2.5M 3 Awards |
$1.7M 4 Awards |
$10.7M |
| 2017 | $60M | 14 | $3.1M 7 Awards |
$4.7M 8 Awards |
$2.4M 3 Awards |
$10.2M |
| Eight-Year Total | $245.7M | $37.65M | $34.2M | $317.55M | ||
* Rally Foundation is the lead advocate for funding to research cancers in pediatric, adolescent and young adult cancers, sarcoma, germ cell cancers, thyroid cancer and lymphoma.
* PAYA funding includes: pediatric, adolescent and young adult cancers, sarcoma, germ cell cancers, thyroid cancer, lymphoma and colorectal cancer.
* DOD will release quantity of awards upon completion of award negotiations.